Comparison of the therapeutic efficacy of 0.1% olopatadine hydrochloride and 0.025% ketotifen fumarate in allergic conjunctivitis

Therapy

Volumn 8, Issue 5, 2011, Pages 545-553

  Sarker, Shah Jalal ^a   Chowdhury, Abu Nayeem ^b   Hussain, Zahid ^c   Hossain, Akm Mosharrof ^d   Chowdhury, Hashem ^d  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b Department of Microbiology   (Bangladesh)

^c SHAHJALAL UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Bangladesh)

^d Sylhet MAG Osmani Medical College   (Bangladesh)

Author keywords

allergic conjunctivitis; efficacy; ketotifen fumarate; olopatadine hydrochloride

Indexed keywords

EYE DROPS; KETOTIFEN FUMARATE; OLOPATADINE;

ABSENCE OF SIDE EFFECTS; ADULT; ALLERGIC CONJUNCTIVITIS; APPLICATION SITE REACTION; APPLICATION SITE STINGING; ARTICLE; CHILD; COMPARATIVE EFFECTIVENESS; CONJUNCTIVAL HYPEREMIA; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRY EYE; EPIPHORA; FEMALE; FOREIGN BODY REACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; OCULAR PRURITUS; PHOTOPHOBIA; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SCORING SYSTEM; SEDATION; SIDE EFFECT; TREATMENT DURATION;

EID: 80053997340     PISSN: 14750708     EISSN: 1744831X     Source Type: Journal    
DOI: 10.2217/thy.11.48     Document Type: Article

References (29)

1. Manzouri B, Flynn TH, Larkin F , Ono SJ, Wyse R. Pharmacotherapy of allergic eye disease. Expert Opin. Pharmacother. 7(9), 1191-1200 (2006). (Pubitemid 43949930)
2. Bielory L. Current reviews of allergy and clinical immunology. J. Allergy Clin. Immunol. 106(6), 1019-1032 (2000).
3. Singh K, Axelrod S, Bielory L. The epidemiology of ocular and nasal allergy in the United States, 1988-1994. J. Allergy Clin. Immunol. 126, 778-783 (2010).
4. Aguilar AJ. Comparative study of clinical efficacy and tolerance in seasonal allergic conjunctivitis management with 0.1% olopatadine hydrochloride versus 0.05% ketotifen fumarate. Acta Ophthalmol. Scand. 78, 52-55 (2000).
5. Leonardi A, Zafirakis P. Efficacy and comfort of olopatadine versus ketotifen ophthalmic solutions: a double-masked, environmental study of patient preference. Curr. Med. Res. Opin. 20(8), 1167-1173 (2004). (Pubitemid 39120781)
6. Torkildsen G. Effective ocular allergy treatments are dual action. Ophthalmology Times, 1 April (2006).
7. Avunduk AM, Tekelioglu Y, Turk A, Akyol N. Comparison of the effects of ketotifen fumarate 0.025% and olopatadine HCl 0.1% ophthalmic solutions in seasonal allergic conjunctivitis: a 30-day, randomized, double-masked, artificial tear substitute-controlled trial. Clin. Ther. 27(9), 1392-1402 (2005). (Pubitemid 41598370)
8. Brockman HL, Momsen MM, Knudtson JR et al. Interactions of olopatadine and selected antihistamines with model and natural membranes. Ocul. Immunol. Inflamm. 11, 247-268 (2003). (Pubitemid 38021421)
9. Lee JS, Lee JE, Kim N, Oum BS. Comparison of the conjunctival toxicity of topical ocular antiallergic agents. J. Ocul. Pharmacol. Ther. 24(6), 557-562 (2008).
10. Kurt RA, Ucakhan-Gunduz M, Gunduz K. Olopatadine 0.1% and 0.2% ophthalmic solution for the management of ocular allergy. Expert Rev. Opthamol. 5(3), 287-296 (2010).
11. Ohmori K, Hayashi K, Kaise T et al. Pharmacological, pharmacokinetic and clinical properties of olopatadine hydrochloride, a new antiallergic drug. Jpn J. Pharmacol. 88, 379-397 (2002). (Pubitemid 34516564)
12. Kamis U, Ozturk BT, Ozkagnici A, Gunduz K. Comparison of the efficacy of olopatadine hydrochloride 0.1% ophthalmic solution and artificial tears in seasonal allergic conjunctivitis. Acta Ophthalmol. 84, 148-149 (2006). (Pubitemid 43337491)
13. Abelson MB, Ferzola NJ, McWhirter CL, Crampton HJ. Efficacy and safety of single-and multiple-dose ketotifen fumarate 0.025% ophthalmic solution in a paediatric population. Paediatric Allergy Immunol. 15(6), 551-557 (2004). (Pubitemid 40030124)
14. Abelson MB, Turner D. A randomized, double-blind, parallel-group comparison of olopatadine 0.1% ophthalmic solution versus placebo for controlling the signs and symptoms of seasonal allergic. Clin. Ther. 25(3), 931-947 (2003). (Pubitemid 36459699)
15. Abelson MB. A review of olopatadine for the treatment of ocular allergy. Expert Opin. Pharmacother. 5(9), 1979-1994 (2004). (Pubitemid 39236599)
16. McGill J. A review of the use of olopatadine in allergic conjunctivitis. Int. Opthamol. 25(9), 171-179 (2004).
17. Berdy GS, Spangler DL, Bensch G, Berdy SS, Brusatti RC. A comparison of the relative efficacy and clinical performance of olopatadine hydrochloride 0.1% ophthalmic solution and ketotifen fumarate 0.025% ophthalmic solution in the conjunctival antigen challenge model. Clin. Ther. 22, 826-833 (2000). (Pubitemid 30625915)
18. Borazan M, Karalezli A, Akova YA, Akman A, Kiyici H, Erbek SS. Efficacy of olopatadine HCL 0.1%, ketotifen fumarate 0.025%, epinastine HCL 0.05%, emedastine 0.05% and fluorometholone acetate 0.1% ophthalmic solutions for seasonal allergic conjunctivitis: a placebo-controlled environmental trial. Acta Ophthalmol. 87, 549-554 (2009).
19. Ganz M, Koll E, Gausche J Detjen P, Orfan N. Ketotifen fumarate and olopatadine hydrochloride in the treatment of allergic conjunctivitis: a real world comparison of efficacy and ocular comfort. Adv. Ther. 20(2), 79-91 (2003). (Pubitemid 36667538)
20. Hida WT, Nogueira DC, Schaefer A, Dantas PEC, Dantas MCN. Comparative study between 0.025% ketotifen fumarate and 0.1% olopatadine hydrochloride in the treatment of vernal keratoconjunctivitis. Arq. Bras. Oftalmol. 69(6), 851-856 (2006).
21. Roy BC, Rahman M, Shahid H. Vernal Keratoconjunctivitis and its response to therapy. J. Bangladesh Acad. Opthamol. 8(2), 53-54 (2001).
22. Yaylali V, Demirlenk I, Tatlipinar S et al. Comparative study of 0.1% olopatadine hydrochloride and 0.5% ketorolac tromethamine in the treatment of seasonal allergic conjunctivitis. Acta Ophthalmol. Scand. 81(4), 378-382 (2003). (Pubitemid 36926866)
23. Riedi CA, Rosario NA. Prevalence of allergic conjunctivitis: a missed opportunity? Allergy 65, 130-139 (2010).
24. Neto HJC, Rosario NA, Westphal GLC, Riedi CA, Santos HLB. Allergic conjunctivitis in asthmatic children: as common as underreported. Ann. Allergy Asthma Immunol. 105, 399-400 (2010).
25. Varguez-Rodríguez ME, Hernández-López A, Gómez-Dávila Rde L. Comparison of olopatadin and ketotifen in the treatment of allergic conjunctivitis. Rev. Med. Inst. Mex. Seguro Soc. 47(4), 399-404 (2009).
26. Leonardi A, Quintieri L. Olopatadine: a drug for allergic conjunctivitis targeting the mast cell. Expert Opin. Pharmacother. 11(6), 969-981 (2010).
27. Figus M, Fogagnolo P, Lazzeri S et al. Treatment of allergic conjunctivitis: results of a 1-month, single-masked randomized study. Eur. J. Opthamol. 20(5), 811-818 (2010).
28. Lichtenstein SJ, Abelson MB. Pharmacology, clinical efficacy and safety of olopatadine hydrochloride. Expert Rev. Clin. Immunol. 2(11), 341-351 (2006). (Pubitemid 44355566)
29. Artal MN, Luna JD, Discepola M. A forced choice comfort study of olopatadine hydrochloride 0.1% versus ketotifen fumarate 0.05%. Acta Ophthalmol. Scand. 78, 64-65 (2000).